Medifast, Inc. Announces First Quarter 2021 Financial Results
Company Added
Company Removed
Apply to Request List

Medifast, Inc. Announces First Quarter 2021 Financial Results

BALTIMORE, May 4, 2021 // PRNewswire // - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the first quarter ended March 31, 2021.

First Quarter 2021 Highlights Compared to the Prior-Year Period

  • Revenue increased 90.9% to $340.7 million
  • 61.0% growth in active earning OPTAVIA Coaches to a record level of 52,500
  • Revenue per active earning OPTAVIA Coach increased 21.0% to $6,454
  • Net income increased 122.2% to $41.1 million
  • Earnings per diluted share ("EPS") of $3.46, an increase of 121.8%

"This has been an exceptional quarter of growth and productivity, reflecting the outstanding abilities of both our independent OPTAVIA Coaches and our employees," said Dan Chard, Chairman and Chief Executive Officer of Medifast.  "We now have a record 52,500 OPTAVIA Coaches who are achieving new productivity highs by leveraging technology to support Clients and support new OPTAVIA Coaches. These technologies include our own app-based platforms as well as social media channels and field-led training platforms. Consumer interest in health and wellness remains high, and the strength of the OPTAVIA coach-based model and its role in transforming lives has continued to attract robust numbers of new Clients. By harnessing demand and leveraging our organizational capabilities, we have amplified revenue and earnings growth to record levels. We're continuing to build infrastructure to capitalize further on future growth opportunities, while also maintaining a strong balance sheet and prioritizing capital allocation to drive long-term stockholder value."

First Quarter 2021 Results

First quarter revenue increased 90.9% to $340.7 million from revenue of $178.5 million for the first quarter of 2020. OPTAVIA-branded products represented 88.9% of consumable units sold for the first quarter compared to 79.0% for the same period a year ago.  Consistent with business and brand strategy, the company decided to sunset the Medifast-branded product line by the end of the second quarter of 2021.

The total number of active earning OPTAVIA Coaches increased 61.0% to 52,500 compared to 32,600 for the first quarter of 2020. The average revenue per active earning OPTAVIA Coach was $6,454 compared to $5,333 for the first quarter last year, an increase of 21.0%.

Gross profit increased 83.8% to $248.5 million from $135.2 million for the first quarter of 2020. The company's gross profit as a percentage of revenue was 73.0% compared to 75.8% in the first quarter of 2020.  The decrease in gross profit as a percentage of revenue was due to the acceleration of demand in OPTAVIA-branded products that led to the increase in the company's use of co-manufacturers and the increased need to provide expedited shipments of our products to keep customer experience at acceptable levels in advance of our fulfillment capacity being fully on-line, both of these items increased costs. Additionally, gross profit as a percentage of revenue decreased due to inventory write-offs related to the sunset of Medifast-branded product line.

Selling, general, and administrative expenses ("SG&A") increased 75.2% to $195.7 million compared to $111.7 million for the first quarter of 2020, primarily due to higher OPTAVIA commission expense, increased salaries and benefits related expenses for employees and increased credit card fees stemming from higher sales. SG&A as a percentage of revenue decreased 510 basis points year-over-year to 57.5% of revenue.

Income from operations increased $29.3 million to $52.8 million from $23.5 million in the prior-year period reflecting higher sales and gross profit and a reduction in the SG&A expense as a percentage of revenue.  Income from operations as a percentage of revenue was 15.5% for the quarter, an increase of 230 basis points from the year-ago period.

The effective tax rate was 22.3% for the first quarter of 2021 compared to 21.8% in the prior-year period.  The slight increase in the effective tax rate was primarily driven by an increase in the state income tax rate and limitations on the deductibility of officer compensation offset by an increase in the tax benefit of stock compensation.

First quarter net income was $41.1 million, or $3.46 per diluted share, based on approximately 11.9 million shares of common stock outstanding. In the first quarter of 2020, net income was $18.5 million, or $1.56 per diluted share, based on approximately 11.8 million shares of common stock outstanding.

Balance Sheet

The company's balance sheet remains strong with cash, cash equivalents and investment securities of $212.9 million as of March 31, 2021 compared to $174.5 million at December 31, 2020.  As of March 31, 2021, the company remained free of interest-bearing debt. On April 13, 2021, the company entered into a credit agreement that provides for a $125.0 million senior secured revolving credit facility with a $20.0 million letter of credit sublimit. The credit agreement also provides for an uncommitted incremental facility that permits the company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $100.0 million.  As of May 4, 2021, no amounts have been borrowed under the credit agreement.

The company declared and paid a quarterly cash dividend of $13.4 million, or $1.13 per share, on February 5, 2021. On March 18, 2021, the Company declared an approximately 26.0% increase in the quarterly dividend to $1.42 per share payable on May 6, 2021. Also during the first quarter of 2021, the company used $7.5 million to repurchase shares of common stock and there are approximately 2.3 million shares remaining under the company's stock repurchase program. 

Outlook

The Company expects full-year 2021 revenue to be in the range of $1.4 billion to $1.475 billion and full-year 2021 EPS to be in the range of $12.69 to $14.14. The full-year 2021 earnings guidance assumes a 23.0% to 24.0% effective tax rate.

Conference Call Information

The conference call is scheduled for today, Tuesday, May 4, 2021 at 4:30 p.m. ET.

Forward Looking Statements

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend," "anticipate," "expects" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of the management of Medifast and are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, risks associated with Medifast's direct-to-consumer business model, the impact of rapid growth on Medifast's systems, disruptions in Medifast's supply chain, Medifast's inability to continue to develop new services and products, effectiveness of Medifast's advertising and marketing programs, including use of social media by independent OPTAVIA Coaches, Medifast's inability to maintain and grow the network of independent OPTAVIA Coaches, the departure of one or more key personnel, Medifast's inability to protect against online security risks, to protect its brand, to protect against product liability claims, Medifast's planned growth into domestic and international markets, adverse publicity associated with Medifast's products or business units, Medifast's inability to continue declaring dividends, fluctuations of Medifast's common stock market price,  the impact of the COVID-19 pandemic on Medifast's results, the severity, length and ultimate impact of the COVID-19 pandemic on people and economies, increases in competition, litigation, consequences of other geopolitical events, natural disasters, acts of war, or climate change, activist investors, regulatory changes, market conditions and resulting impact on consumer spending, and a failure of internal control over financial reporting. Although Medifast believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(U.S. dollars in thousands, except per share amounts & dividend data)

 
   

Three months ended March 31,

   

2021

 

2020

             

Revenue

 

$

340,669

 

$

178,461

Cost of sales

   

92,122

   

43,221

Gross profit

   

248,547

   

135,240

             

Selling, general, and administrative

   

195,748

   

111,707

             

Income from operations

   

52,799

   

23,533

             

Other income 

           

Interest income, net

   

23

   

110

Other income (expense)

   

19

   

(19)

     

42

   

91

             

Income from operations before income taxes

   

52,841

   

23,624

             

Provision for income taxes

   

11,778

   

5,147

             

Net income

 

$

41,063

 

$

18,477

             

Earnings per share - basic

 

$

3.49

 

$

1.57

             

Earnings per share - diluted

 

$

3.46

 

$

1.56

             

Weighted average shares outstanding 

           

Basic

   

11,772

   

11,772

Diluted

   

11,881

   

11,824

             

Cash dividends declared per share

 

$

1.42

 

$

1.13

 

MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(U.S. dollars in thousands, except par value)

 
       

March 31,

   

December 31,

       

2021

   

2020

               

ASSETS

Current Assets

             

Cash and cash equivalents

   

$

206,031

 

$

163,723

Accounts receivable-net of doubtful accounts of $383 and $219 at 

             

March 31, 2021 and December 31, 2020, respectively

     

88

   

584

Inventories

     

62,234

   

53,392

Investment securities

     

6,883

   

10,752

Prepaid expenses and other current assets

     

6,625

   

5,863

Total current assets

     

281,861

   

234,314

               

Property, plant and equipment - net of accumulated depreciation

     

31,107

   

27,633

Right-of-use assets

     

9,623

   

10,508

Other assets

     

3,112

   

2,937

Deferred tax assets

     

692

   

692

               
               

TOTAL ASSETS

   

$

326,395

 

$

276,084

               

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities

             

Accounts payable and accrued expenses

   

$

141,250

 

$

107,677

Current lease obligations

     

3,651

   

3,673

Total current liabilities

     

144,901

   

111,350

               

Lease obligations, net of current lease obligations

     

6,603

   

7,488

Total liabilities

     

151,504

   

118,838

               

Stockholders' Equity

             

Common stock, par value $.001 per share: 20,000 shares authorized;

             

11,839 and 11,822 issued and 11,761 and 11,772 outstanding

             

at March 31, 2021 and December 31, 2020, respectively

     

12

   

12

Additional paid-in capital

     

8,714

   

7,842

Accumulated other comprehensive income

     

103

   

41

Retained earnings 

     

178,562

   

154,351

Less: treasury stock at cost, 76 and 46 shares at March 31, 2021 and
December 31, 2020, respectively

     

(12,500)

   

(5,000)

Total stockholders' equity

     

174,891

   

157,246

               

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

   

$

326,395

 

$

276,084

SOURCE Medifast, Inc.

###

Comments:

comments powered by Disqus

Subscribe to Our Newsletters